Ipca Labs

Emkay predicts strong upside in Ipca Labs shares on India, export growth

Emkay Global initiated coverage of Ipca Labs shares with 'Buy' rating and a share price target of ₹1,700 -- a 19 per cent upside from current levels

Ipca Labs jumps 7% after Q2 results; buy, sell or hold? Analysts suggest

Ipca Laboratories share price was trading 6.2 per cent higher at ₹1,382.60 compared to previous session's close of ₹1,302 on the NSE

Pharma in bitter health: Stocks sink upto 38% in 2025; time to bottom fish?

Among stocks, Natco Pharma plunged 37.85%, Ipca Labs 22.43%, Aurobindo Pharma 17.99%, and Sun Pharma 14.30%. Other laggards include Lupin (13.25%), and Dr Reddy's (5.17%).

Dr Reddy's Labs, Lupin: Nifty Pharma slips 2% amid Trump tariff jitters

Nifty Pharma index declined 1.5 per cent in trade after US President Donald Trump warned to impose a 25 per cent tariff on Indian goods starting August 1

5 midcap stocks ideas that can deliver up to 24% returns in the short-term

Aurobindo Pharma, IPCA Labs, Oil India, Mazagon Dock and GIC RE are the 5 midcap stocks that can potentially surge up to 24% from present levels, suggests technical charts.

IPCA Laboratories share price jumps 7% after healthy Q3 results; details

Shares of IPCA Laboratories have yielded a return of 8 per cent in the last six months and nearly 30 per cent in the last one year for its investors

Q3 results today: Hindalco, Godfrey Phillips to post earnings on Feb 13

Q3FY25 company results, February 13: United Breweries, Ipca, and SVJN will be among 389 firms releasing their earnings report for the Oct-Dec 2024 quarter

Alkem Labs, Ipca, Divi's: Three reasons why pharma stocks are falling today

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

Rajesh Bhosale of Angel One recommends buying these two stocks on Dec 30

The daily chart indicates a multiple-pattern bullish breakout for Mangalam Cement

Ipca Labs gain 4% after promoter sells 1.6% stake via bulk deal on BSE

As per BSE bulk deal data, the company's promoter Usha M Chandurkar sold 40,00,000 lakh shares for Rs 1,501.52 per share, reducing her holding from 3.27 per cent as of September-end

Ipca Labs Q2 results: PAT rises 58% to Rs 229 cr, revenue at Rs 2,355 cr

Ipca Laboratories on Thursday said its consolidated net profit declined 58 per cent year-on-year to Rs 229 crore in the September quarter. The drug firm had reported a net profit of Rs 145 crore in the year-ago period. Revenue from operations rose to Rs 2,355 crore for the second quarter of the current fiscal year as compared with Rs 2,034 crore in the year-ago period, Ipca Laboratories said in a regulatory filing. The company said its domestic formulations business revenue stood at Rs 940 crore for the quarter, up 11 per cent from Rs 845 crore a year earlier. Export of generics stood at Rs 286 crore in the July-September period as against Rs 264 crore, registering a year-on-year growth of 8 per cent. The company said its board has approved an interim dividend of Rs 21 per share of Re 1 each for 2024-25. Shares of the company on Thursday ended 2.02 per cent up at Rs 1,538.65 apiece on the BSE.

Unichem Laboratories up 5% on pact with Ipca Labs' arm Bayshore Pharma

Unichem Labs share price: Unichem Laboratories' board has approved asset purchase agreement with Bayshore Pharmaceuticals

Ipca Labs shares hit lifetime high after Nomura raises target price

Ipca laboratories share price surged up to 3.66 per cent intraday, hitting their all time high at Rs 1509.45 per share on the BSE

IPCA Labs targets Rs 100 crore market with new diabetic foot ulcer drug

This drug has shown a 77.20 per cent ulcer closure rate in clinical trials, offering hope for a condition that often leads to severe outcomes like lower limb amputations

Ipca Labs may outpace past 5-year growth ahead, analysts say buy the dips

Shares of Ipca Labs slipped 2.82 per cent to Rs 1312.55 per share on the BSE in Friday's early morning trade

Ipca Labs Q1 results: Net profit up 18% at Rs 192 cr on robust sales

Ipca Laboratories on Tuesday said its consolidated net profit increased 18 per cent to Rs 192 crore for the first quarter ended June 30, 2024 aided by robust sales in the domestic market. The drug firm had reported a net profit of Rs 163 crore for the April-June period of last fiscal. Revenue from operations rose to Rs 2,093 crore for the April-June quarter, as compared to Rs 1,585 crore in the year-ago period, Ipca Laboratories said in a regulatory filing. The drug firm said domestic formulations income rose 12 per cent year-on-year to Rs 873 crore in the first quarter. Exports income, however, declined 4 per cent year-on-year to Rs 591 crore during the June quarter, the company said. Shares of Ipca Laboratories on Tuesday closed 1.33 per cent up at Rs 1,400 apiece on the BSE.

HUL, Ipca Lab, Bikaji: Top stock picks by Chandan Taparia of Motilal Oswal

Hindustan Unilever is in overall uptrend and is on the verge of giving Pole and Flag pattern breakout on daily chart

EU Court upholds Rs 126 cr fine imposed on Ipca Labs' unit; stock jumps 4%

The uptick in share price came after the company announced that the EU Court upheld Rs 126 crore fine imposed on Ipca Labs' unit, Unichem Laboratories

Ipca Labs Q3 results: Profit up 67% at Rs 180 cr, revenue at Rs 2,053 cr

Ipca Laboratories on Wednesday reported 67 per cent increase in consolidated net profit at Rs 180 crore for the third quarter ended December 31, 2023. The drugmaker had reported a net profit of Rs 108 crore for October-December FY23. Revenue from operations rose to Rs 2,053 crore from Rs 1,546 crore in the year-ago period, Ipca Laboratories said in a regulatory filing. Shares of the company were trading 0.86 per cent down at Rs 1,150.15 apiece on the BSE.

Ipca Laboratories acquires 33.38% stake in Unichem for over Rs 945 cr

Ipca Laboratories on Wednesday said it has completed the acquisition of a 33.38 per cent stake in Unichem for Rs 945.35 crore. Last week, Ipca got approval from the Competition Commission of India (CCI) for a 59.38 per cent stake purchase in listed Unichem Laboratories. "Post receipt of approval of CCI, the company has acquired 2,35,01,440 fully paid-up equity shares of Rs 2 each, constituting about 33.38 per cent of the paid-up equity share capital of Unichem Laboratories from one of Unichem's promoter shareholders, at a price of Rs 402.25 per equity share aggregating to Rs 945.35 crore," Ipca said in a regulatory filing. The deal was executed through a block deal on the National Stock Exchange (NSE), it added. Ipca has already made an open offer to Unichem's shareholders to acquire another 26 per cent of the fully diluted outstanding equity share capital of the company at a price of Rs 440 per share, aggregating to Rs 805.44 crore. The Draft Letter of Offer (DLOF) for the open o